ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare Return on Assets Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FROHHYPOTHETICAL MODEL
Since ’99
−89%
Expense Ratio
0.45%
placeholder
Holdings
96
cap-weighted
Inception
Feb 2021
placeholder
Full Sharpe
0.02
Ann. Return (LS)
0.8%
Ann. Volatility
33.6%
Max Drawdown
-95.4%
Test Sharpe ’19–26
0.18
Test FF5 α (ann.)
-2.1%
vs Fama-French 5
Test FF5 α t-stat
-0.28
not significant
Monthly turnover
7%
of the long leg, per rebalance
Cumulative return (LS)
-89%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.61
what this fund holds
Long leg ann. return
8.9%
buyable, long-only
Long-short Sharpe
0.02
requires shorting
Bottom bucket ann. return
8.1%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

96 of 96 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
26.49%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
14.53%
3MRK
MERCK & CO INCHealthcare$314.90B
7.51%
4TMO
THERMO FISHER SCIENTIFIC INCHealthcare$197.88B
4.72%
5AMGN
AMGEN INCHealthcare$197.69B
4.72%
6GILD
GILEAD SCIENCES INCHealthcare$166.72B
3.98%
7BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
2.96%
8VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
2.94%
9SYK
STRYKER CORPHealthcare$122.63B
2.93%
10ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
2.92%
11MCK
MCKESSON CORPHealthcare$101.14B
2.41%
12HCA
HCA HEALTHCARE INCHealthcare$82.34B
1.96%
13REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
1.69%
14BSX
BOSTON SCIENTIFIC CORPHealthcare$65.44B
1.56%
15EW
EDWARDS LIFESCIENCES CORPHealthcare$49.36B
1.18%
16IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
1.07%
17A
AGILENT TECHNOLOGIES INCHealthcare$37.13B
0.89%
18ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
0.85%
19ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.83%
20ZTS
ZOETIS INCHealthcare$32.10B
0.77%
21VEEV
VEEVA SYSTEMS INCHealthcare$31.74B
0.76%
22DXCM
DEXCOM INCHealthcare$29.58B
0.71%
23RMD
RESMED INCHealthcare$28.86B
0.69%
24ILMN
ILLUMINA INCHealthcare$28.24B
0.67%
25MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
0.63%
26WST
WEST PHARMACEUTICAL SERVICES INCHealthcare$25.31B
0.60%
27INCY
INCYTE CORPHealthcare$23.42B
0.56%
28DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
0.56%
29UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.54%
30STE
STERIS PLCHealthcare$21.26B
0.51%
31NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.41%
32MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
0.37%
33SOLV
SOLVENTUM CORPHealthcare$14.08B
0.34%
34EXEL
EXELIXIS INCHealthcare$14.06B
0.34%
35ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.30%
36PEN
PENUMBRA INCHealthcare$12.52B
0.30%
37PODD
INSULET CORPHealthcare$11.36B
0.27%
38EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.27%
39KRYS
KRYSTAL BIOTECH INCHealthcare$10.46B
0.25%
40GMED
GLOBUS MEDICAL INCHealthcare$10.45B
0.25%
41ENSG
ENSIGN GROUP INCHealthcare$10.01B
0.24%
42CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.23%
43HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.22%
44UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.22%
45ATR
APTARGROUP INCHealthcare$8.46B
0.20%
46TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.20%
47HQY
HEALTHEQUITY INCHealthcare$8.17B
0.19%
48LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.17%
49CHE
CHEMED CORPHealthcare$6.77B
0.16%
50LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
0.15%
51KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.12%
52VCYT
VERACYTE INCHealthcare$4.72B
0.11%
53ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.10%
54CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.10%
55DOCS
DOXIMITY INCHealthcare$3.94B
0.09%
56CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.09%
57NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.09%
58OPCH
OPTION CARE HEALTH INCHealthcare$3.41B
0.08%
59GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.06%
60TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
0.06%
61PGNY
PROGYNY INCHealthcare$2.50B
0.06%
62LMAT
LEMAITRE VASCULAR INCHealthcare$2.32B
0.06%
63MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.05%
64ADUS
ADDUS HOMECARE CORPHealthcare$2.14B
0.05%
65AVAH
AVEANNA HEALTHCARE HOLDINGS INCHealthcare$2.11B
0.05%
66AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.05%
67ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.05%
68HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.05%
69UFPT
UFP TECHNOLOGIES INCHealthcare$1.87B
0.04%
70ANIP
ANI PHARMACEUTICALS INCHealthcare$1.80B
0.04%
71HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.04%
72INVA
INNOVIVA INCHealthcare$1.60B
0.04%
73INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.03%
74PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.03%
75IRMD
IRADIMED CORPHealthcare$1.24B
0.03%
76NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.03%
77TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.02%
78ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.02%
79RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.02%
80OMER
OMEROS CORPHealthcare$701M
0.02%
81CRMD
CORMEDIX INCHealthcare$661M
0.02%
82TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.02%
83XOMA
XOMA ROYALTY CORPHealthcare$504M
0.01%
84NRC
NRC HEALTHHealthcare$491M
0.01%
85VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.01%
86PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.01%
87ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.01%
88ELMD
ELECTROMED INCHealthcare$349M
0.01%
89QTTB
Q32 BIO INCHealthcare$255M
0.01%
90SPOK
SPOK HOLDINGS INCHealthcare$222M
0.01%
91UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.01%
92AGEN
AGENUS INCHealthcare$209M
0.00%
93PDEX
PRO DEX INCHealthcare$183M
0.00%
94INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
95LNSR
LENSAR INCHealthcare$70M
0.00%
96SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $4.19T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

96 classified
Value
Blend
Growth
Large
Mid
Small
15%11
44%24
40%21
<1%8
<1%6
<1%6
<1%9
<1%10
<1%1

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 62% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt62% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 96 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
3
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    66.5%
    Margin
    -8.5%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    26.5%
    Margin
    -1.5%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 96 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
0.9 (95% CI 0.7-1.0)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
8.7%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
0.90x
within
parametric
0.92x
within
cornish fisher
0.82x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
69%
18 of 26 3-year windows made money
Worst window
-0.68
Sharpe, January 2003 – December 2005
January 1999July 2026
Median Sharpe
0.10
Dispersion
0.40
Best window
0.99

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.24.6%-24.1%
3 yearsp.a.9.5%-15.1%
5 yearsp.a.5.9%1.3%
10 yearsp.a.10.3%1.7%
Since inceptionp.a.8.1%-7.8%
Calendar years
YearLong legLong-short
20267 mo2.5%-12.9%
202518.4%-26.3%
20244.3%16.4%
20233.1%-29.9%
2022-4.6%47.0%
202127.8%87.6%
202017.8%-17.0%
201918.2%-10.4%
20187.1%23.1%
201721.2%-4.2%
20160.1%16.6%
20153.9%4.0%
201423.8%-7.2%
201341.1%-1.6%
201219.2%-14.4%
201113.4%19.1%
20104.6%-9.2%
200921.3%-0.8%
2008-17.5%8.1%
20076.2%13.2%
20066.7%2.2%
20052.7%6.0%
20044.7%-7.6%
20038.3%-40.9%
2002-20.7%62.6%
2001-15.1%-4.9%
200035.9%-87.7%
1999-3.4%-40.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FROH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-02-10 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$4.19T

Methodology

The Foundry Healthcare Return on Assets Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Return on Assets signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.